Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268 HK) with a target price of HKD 91.00, indicating a potential upside of 62.1% from the current price of HKD 56.15 [1][5][11]. Core Insights - The company is expected to continue strong growth in 2025, with significant performance in financial metrics and order intake. A key turning point is anticipated in 2026 with a surge in M-end production projects, projecting a total of 30 BLA submissions from 2026 to 2028, which will drive new growth [2][7]. - The report highlights the company's competitive advantages in technology and service capabilities, particularly in the high-growth XDC CRDMO sector, and emphasizes the potential for market share expansion [2][5]. Financial Performance - For 2025, the company recorded a revenue increase of 46.7% and an adjusted net profit increase of 69.9%, aligning with previous forecasts [7]. - The gross margin improved significantly by 5.4 percentage points to 36.0%, attributed to enhanced capacity utilization and operational efficiency [7]. - The company anticipates revenue growth exceeding 40% in 2026, factoring in the consolidation of Dongya, with organic growth projected to surpass 35% [7]. Earnings Forecast Adjustments - The updated earnings forecasts for 2026-2028 show a slight increase in revenue projections, with 2026 revenue expected at RMB 8,331 million, a 1% increase from previous estimates [6]. - Adjusted net profit for 2026 is forecasted at RMB 2,173 million, reflecting a 5% decrease from prior estimates, while the adjusted net profit margin is expected to be 26.1% [6]. Market Position and Growth Drivers - The company signed a record 70 iCMC projects and added 10 PPQ projects in 2025, with a backlog of over USD 1.49 billion, indicating strong demand [7]. - The report notes that over 50% of new iCMC projects involve innovative coupling drugs, and the company is set to expand its production capacity significantly, including a new GMP facility in Singapore expected to commence operations in the second half of 2026 [7][8]. - Management projects that by 2030, revenue from XDC molecules and M-end projects will each account for 20% of total revenue [7].

Core Viewpoint - WuXi AppTec (02268) has demonstrated exceptional performance in the bioconjugate drug CRDMO sector, with a revenue growth of 62.2% in the first half of 2025, significantly surpassing annual growth guidance, and achieving a compound annual growth rate (CAGR) of 98% from the first half of 2022 to the first half of 2025, solidifying its leading position in the industry [1][2][4]. Financial Performance - The company's revenue for the first half of 2025 reached 2.701 billion yuan, a year-on-year increase of 62.2%, with a gross profit of 975 million yuan, up 82.2%, and a gross margin of 36.1%, reflecting a 5.5 percentage point increase from the full year of 2024 [2][4]. - Adjusted net profit, excluding interest income and expenses, was 733 million yuan, representing a 69.6% year-on-year growth [2]. Market Position and Growth - WuXi AppTec's market share in the bioconjugate drug CRDMO sector has surged from 9.9% in 2022 to approximately 22% in the first half of 2025, indicating strong market penetration and growth [7][11]. - The company signed a record 37 new iCMC projects in the first half of 2025, with a focus on innovative ADC molecules, including bispecific ADCs and multi-load ADCs [4][12]. Client Engagement and International Expansion - The number of global clients increased to 563, with 64 new clients added in the first half of 2025, including 13 of the top 20 global pharmaceutical companies [4][11]. - Approximately 82% of the company's revenue in the first half of 2025 came from international markets, highlighting its role as a preferred partner for overseas pharmaceutical companies [11]. Production Capacity and Infrastructure - The new DP3 production facility in Wuxi has been successfully GMP released, with an annual capacity of 7 million bottles, increasing the overall DP capacity to 15 million bottles [15][19]. - The company is also advancing its global strategy with a new production base in Singapore, expected to achieve GMP release by the first half of 2026 [19][22]. Technological Advancements - WuXi AppTec has made significant investments in technology, launching new payload linker technologies, WuXiTecan-1 and WuXiTecan-2, to enhance its service offerings [29]. - The company has advanced 1,000 molecules in early research for XDC, with a focus on high-difficulty ADC types, ensuring a robust pipeline for future growth [25][29]. Conclusion - WuXi AppTec's strong project reserves, efficient capacity construction, and strategic focus on innovative ADC and bioconjugate drug development position it as a leader in the CRDMO sector, driving sustained high growth [32].